MHRA - Guidance on pharmacovigilance requirements for UK authorised products from 1 January 2021

12th February 2021

Since before the end of the transition period on 31st December 2020, MHRA have been working hard to provide the guidance you need to become familiar with the pharmacovigilance requirements for UK marketing authorisation holders (MAH) which are set out in a revised legal framework. In this blog post, Kiernan Trevett has pulled together all the sources of guidance that MHRA have published so far, as well as information on where to go if you still have questions.

Read here

Back to News Archive